AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Novuspharma SpA results of BBR 2778 study show potential.(product testing)(Brief Article)
2002 AUG 5 - (NewsRx.com & NewsRx.net) -- Novuspharma SpA (NOV.MI), a biotechnology company focused on cancer, announced results from a preclinical study with BBR 2778 in a chronic model of multiple sclerosis.
The results were presented by Dr. Guido Cavaletti of the Bicocca University of Milan, together with colleagues and Novuspharma scientists, at the 12th Meeting of the European Neurological Society in Berlin June 22-26, 2002. BBR 2778 is Novuspharma's intercalating agent currently in phase III clinical trials for the treatment of non-Hodgkin lymphoma.
The aim of the preclinical experiments was to examine the effect of BBR 2778 in a chronic, relapsing, experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis by comparing BBR 2778 with mitoxantrone, an anticancer drug approved in U.S. and certain European countries for the treatment of multiple sclerosis.
The data analyzed so far indicate that ...
- Novuspharma SpA Announces Results of BBR 2778 Study Show Potential in Chronic...
- Press release article from: Business Wire June 24, 2002 700+ words
...Neurological Society in Berlin Novuspharma SpA (Nuovo Mercato:NOV...preclinical study with BBR 2778 in a chronic model...22 to 26 June 2002. BBR 2778 is Novuspharma...c.$3bn by 2004. Novuspharma SpA Novuspharma, based...anti-cancer drug, BBR 2778, has recently...
- Novuspharma SpA results of BBR 2778 study show potential.
- Newspaper article from: Drug Week August 9, 2002 700+ words
...com & NewsRx.net) -- Novuspharma SpA (NOV.MI), a biotechnology...from a preclinical study with BBR 2778 in a chronic model of multiple...Berlin June 22-26, 2002. BBR 2778 is Novuspharma's intercalating...was to examine the effect of BBR 2778 in a chronic, relapsing...
- New Generation Drug Effective, Reduces Cardiotoxicity.(BBR 2778 from...
- Newspaper article from: Health & Medicine Week July 23, 2001 700+ words
...23 - (NewsRx Network) -- Novuspharma SpA (NO V.MT), announced that...Drug Administration (FDA) for BBR 2778, a compound for treating...dose-escalation studies with BBR 2778 in the U.S. at the M...determine the safest regimen for BBR 2778 when administered in combination...
- Novuspharma SpA Announces Plans for Phase I Trial of Pixantrone (BBR 2778) in...
- Press release article from: PR Newswire December 2, 2002 700+ words
BRESSO, Italy -- Novuspharma SpA (Nuovo Mercato: NOV.MI), a biopharmaceutical company primarily...today announces plans to begin a phase I trial of pixantrone (BBR 2778) in patients with multiple sclerosis (MS) in early 2003...
- NOVUSPHARMA SPA ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED 30...
- Press release article from: PR Newswire November 13, 2001 700+ words
...transmitted on behalf of Novuspharma SpA. Co-founders and managers...agreement Bresso, Italy - Novuspharma SpA (Nuovo Mercato: NOV...2004. Highlights: * BBR 2778 commenced recruitment...to begin by year end * BBR 2778 European Phase II...
- Novuspharma SpA Announces Financial Results for the Third Quarter Ended 30...
- Press release article from: PR Newswire November 13, 2001 700+ words
...Nov. 13 /PRNewswire/ -- Novuspharma SpA (Nuovo Mercato: NOV.MI...November 2004. Highlights: * BBR 2778 commenced recruitment for...expected to begin by year end * BBR 2778 European Phase II trial...at DHGO meeting in Mannheim * BBR 3438/3576 commenced recruitment...
- Novuspharma SpA Announces Financial Results for the Three Months Ended 31 March...
- Press release article from: PR Newswire May 14, 2003 700+ words
Novuspharma SpA (Nuovo Mercato...for pixantrone (BBR 2778) in indolent...phase II study for BBR 3576 in patients...phase II study for BBR 3576 in prostate...CONTACT: Karl Hanks of Novuspharma SpA, +39-02-61035807...
- Novuspharma SpA Announces Results For The Third Quarter.(Brief Article)
- Newspaper article from: Cancer Weekly December 18, 2001 700+ words
...com & NewsRx.net) -- Novuspharma SpA (NOV.MI) has reported financial...November 2004. Highlights: * BBR 2778 commenced recruitment for...expected to begin by year end * BBR 2778 European Phase II trial...at DHGO meeting in Mannheim * BBR 3438/3576 commenced recruitment...
